Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIUNASDAQ:DMACNASDAQ:HURANASDAQ:VTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$1.53-2.5%$1.78$1.43▼$4.98$153.63M1.62180,956 shs87,639 shsDMACDiaMedica Therapeutics$4.00+0.5%$4.19$2.14▼$6.82$171.42M1.2977,938 shs210,892 shsHURATuHURA Biosciences$3.89-5.1%$3.61$1.80▼$7.93$169.92M0.53250,208 shs85,736 shsVTLVital Therapies$0.99+0.3%$8.88$0.15▼$9.75$41.94M3.5121.62 million shs570,486 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune-2.55%-7.83%+0.66%-42.91%-57.26%DMACDiaMedica Therapeutics+0.50%+3.09%+12.99%-36.00%+32.45%HURATuHURA Biosciences-5.12%+2.64%-7.38%-15.07%+388,999,900.00%VTLVital Therapies+0.31%-7.50%+9.95%+4.18%-22.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACIUAC Immune2.7616 of 5 stars3.53.00.00.02.90.81.3DMACDiaMedica Therapeutics1.4733 of 5 stars3.52.00.00.02.50.00.0HURATuHURA BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AVTLVital TherapiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 3.00Buy$10.00553.59% UpsideDMACDiaMedica Therapeutics 3.00Buy$8.00100.00% UpsideHURATuHURA Biosciences 3.25Buy$12.67225.62% UpsideVTLVital Therapies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VTL, HURA, DMAC, and ACIU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.004/3/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/3/2025HURATuHURA BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.003/19/2025DMACDiaMedica TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/14/2025ACIUAC ImmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/3/2025HURATuHURA BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$13.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$28.30M5.43N/AN/A$2.12 per share0.72DMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AHURATuHURA BiosciencesN/AN/AN/AN/A($4.11) per shareN/AVTLVital TherapiesN/AN/AN/AN/A$0.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$60.41M-$0.58N/AN/AN/AN/A-28.26%-18.98%N/ADMACDiaMedica Therapeutics-$19.38M-$0.60N/AN/AN/AN/A-43.67%-40.81%N/AHURATuHURA Biosciences-$8.32MN/A0.00∞N/AN/AN/A-152.88%N/AVTLVital Therapies-$41.47MN/A0.00∞N/AN/A-235.33%-182.35%N/ALatest VTL, HURA, DMAC, and ACIU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/A4/30/2025Q1 2025ACIUAC Immune-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 million3/17/2025Q4 2024DMACDiaMedica Therapeutics-$0.17-$0.18-$0.01-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/AVTLVital TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.861.86DMACDiaMedica TherapeuticsN/A11.8111.81HURATuHURA BiosciencesN/A1.541.54VTLVital TherapiesN/A6.976.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%DMACDiaMedica Therapeutics10.12%HURATuHURA Biosciences0.62%VTLVital Therapies15.52%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%DMACDiaMedica Therapeutics7.30%HURATuHURA Biosciences0.20%VTLVital Therapies33.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million94.39 millionOptionableDMACDiaMedica Therapeutics2042.86 million39.68 millionOptionableHURATuHURA BiosciencesN/A43.68 million42.20 millionN/AVTLVital Therapies1042.37 millionN/ANot OptionableVTL, HURA, DMAC, and ACIU HeadlinesRecent News About These Companies18,000 vulnerable children could lose ‘vital’ therapy as adoption fund faces axeMarch 31, 2025 | msn.comVeterans Deserve Access To Life-Changing Psychedelics Therapy: A Vital Solution For PTSD And HealingNovember 11, 2024 | benzinga.comRespiratory Therapy program continues to thrive at Vermont State UniversityNovember 6, 2024 | vermontbiz.comRespiratory Therapy program continues to thrive at Vermont State UniversityNovember 6, 2024 | vermontbiz.comLighthouse Center for Vital Living celebrates new buildingOctober 30, 2024 | duluthnewstribune.comAlternative Wellness Therapies in the Tahoe BasinOctober 11, 2024 | tahoedailytribune.comAddressing Trauma: A Vital Component in Behavioral HealthOctober 3, 2024 | ajmc.comVital Care Receives Strategic Investment From Berkshire Partners, Leonard Green & Partners, and Linden Capital PartnersAugust 1, 2024 | tmcnet.comVeterans lobbied for psychedelic therapy, but it may not be enough to save MDMA drug applicationJuly 26, 2024 | msn.comEnding TherapyMay 24, 2024 | psychologytoday.comMedication and TherapyMay 23, 2024 | psychologytoday.comVardhman Textiles Ltd.May 22, 2024 | wsj.comFDA’s Marks: Global Regulatory Convergence Vital to Cell & Gene Therapy OversightMay 11, 2024 | biospace.comVital Spa celebrates a year on Bridge StreetApril 28, 2024 | yahoo.comGuest opinion: Psychedelics as a vital path to healing for veteransApril 28, 2024 | heraldextra.comDon’t Forget About Vital Signs in Psychiatry VisitsMarch 12, 2024 | psychologytoday.comWhat is therapeutic recreation? Champaign counselors train to include it in their sessionsMarch 8, 2024 | yahoo.comTeen Therapy and Psychiatry Online: Hit or Miss?March 3, 2024 | medpagetoday.comVital Ltd VTLMarch 2, 2024 | morningstar.comThe Benefits of Teen Outpatient Programs for Behavioral HealthMarch 2, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVTL, HURA, DMAC, and ACIU Company DescriptionsAC Immune NASDAQ:ACIU$1.53 -0.04 (-2.55%) As of 05/14/2025 04:00 PM EasternAC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.DiaMedica Therapeutics NASDAQ:DMAC$4.00 +0.02 (+0.50%) As of 05/14/2025 04:00 PM EasternDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.TuHURA Biosciences NASDAQ:HURA$3.89 -0.21 (-5.12%) As of 05/14/2025 04:00 PM EasternTuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.Vital Therapies NASDAQ:VTLImmunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
